Sheth-Shah, R; Vernon, AJ; Seetharaman, S; Neale, MH; Daniels, JT; (2016) Regulatory requirements in the good manufacturing practice production of an epithelial cell graft for ocular surface reconstruction. Regenerative Medicine , 11 (3) pp. 307-320. 10.2217/rme-2015-0020.

Preview

Text Daniels_Regerative Medicine_revisions_accepted track changes.pdf Download (835kB) | Preview

Abstract

In the past decade, stem cell therapy has been increasingly employed for the treatment of various diseases. Subsequently, there has been a great interest in the manufacture of stem cells under good manufacturing practice, which is required by law for their use in humans. The cells for sight Stem Cell Therapy Research Unit, based at UCL Institute of Ophthalmology, delivers somatic cell-based and tissue-engineered therapies to patients suffering from blinding eye diseases at Moorfields Eye Hospital (London, UK). The following article is based on our experience in the conception, design, construction, validation and manufacturing within a good manufacturing practice manufacturing facility based in the UK. As such the regulations can be extrapolated to the 28 members stated within the EU. However, the principles may have a broad relevance outside the EU.

Download activity - last month

Export as JSONXMLCSV

Download activity - last 12 months

Export as JSONCSVXML

Downloads by country - last 12 months

Export as JSONCSVXML

Archive Staff Only

View Item